Abstract Details

Title Effects of Corticosteroids on Metabolic Syndrome in Glioblastoma

Topic Neuro-oncology

Presentation(s) Neuro-oncology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 006

Objective To determine the effect of corticosteroids on the development of metabolic syndrome in patients with glioblastoma.

Background Corticosteroid use and subsequent hyperglycemia are common in Glioblastoma and both have been linked to decreased survival. Corticosteroids contribute to key features of metabolic syndrome: obesity, glucose intolerance, hypertension and altered lipid metabolism. We sought to document baseline features of metabolic syndrome and its progression over time.

Design/Methods We performed an IRB approved retrospective chart review of patients with glioblastoma treated at the University of Rochester Medical Center and documented serum glucose, blood pressure, weight and corticosteroid use from diagnosis until death.

Results 170 patients with GBM from 2010 to 2019 were identified. Median age was 61. (61.8% men, 38.2% women) 59 were tapered off of steroids after surgery and had decline in median serum glucose (102mg/dL to 97), a decline in mean systolic BP (129 to 126), a decline in mean diastolic BP (76 to 74) and a decline in weight (82 kg to 79). 48 patients with >9 months corticosteroids had higher baseline values which remained stable or increased over time: median serum glucose increased from 113 to 114, SBP increased from 132 to 136, DBP remained at 78 and most notably, weight increased from 84kg to 90kg. 63 patients were on corticosteroids intermittenlty and remained stable with only modest changes in the long term: median serum glucose increased from 108 to 109, SBP decreased from 133 to 129.5, DBP decreased from 78 to 75, and weight decreased from 84kg to 82kg

Conclusions

Our findings suggest that chronic corticosteroid use in glioblastoma contributes to some increases in measures of metabolic syndrome, and in particular, to an increase in weight. Overall changes in our cohort were minor, suggesting that these values may not be sensitive biomarkers of the added metabolic burden of corticosteroids.

Authors/Disclosures
Varun Mehta, MD (University of Rochester School of Medicine and Dentistry) PRESENTER	Varun Mehta has nothing to disclose.
Nimish A. Mohile, MD, FAAN	The institution of Dr. Mohile has received research support from Novocure.

��ɫ��

��ɫ��